Journal of Computer Science and Technology Studies
ISSN: 2709-104X
DOI: 10.32996/jcsts
Journal Homepage: www.al-kindipublisher.com/index.php/jcsts

JCSTS
AL-KINDI CENTER FOR RESEARCH
AND DEVELOPMENT

| RESEARCH ARTICLE

AI-Driven Big Data Analytics for Personalized Cancer Treatment: Integrating Multi-Omics, Medical Imaging, and Predictive Intelligence

1. **Md. Ishtiaque Alam**
Orfalea College of Business, California Polytechnic State University, San Luis Obispo, CA, USA
ORCID ID: https://orcid.org/0009-0005-1108-1015

2. **Mohammad Abdus Sami**
Department of Business Administration, California State Polytechnic University, Pomona, CA, USA
ORCID ID: https://orcid.org/0009-0004-6074-4842

3. **Abdullah Al Masud**
Department of Geography and Environmental Studies, California State University, Northridge, CA, USA
ORCID ID: https://orcid.org/0009-0007-8027-0439

4. **Hossain Ahmed**
Department of Information Systems, Pacific States University, Los Angeles, CA, USA
ORCID ID: https://orcid.org/0009-0006-9145-8958

5. **Forhad Hossain**
Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
ORCID ID: https://orcid.org/0009-0003-9613-4723

Corresponding author: Md. Ishtiaque Alam, **Email**: ishti99@yahoo.com

| ABSTRACT

Cancer treatment still faces some major challenges - tumors are highly variable, diagnosis is slow, and treatments are not well personalized. Traditional cancer care is based on generalized treatment strategies and does not take into consideration the unique genetic, clinical, and environmental variations of each individual patient. Recent advances in big data analysis, artificial intelligence (AI), and machine learning (ML) have begun to bring personalized cancer care. In this shift, decisions are made using a large amount of medical data of varying nature. This paper provides an overview of big data frameworks based on Artificial Intelligence (AI) for the personalized treatment of cancer. It combines clinical data, multi-omics data, and advanced imaging. Using proven techniques and emerging research, the paper demonstrates how deep learning and predictive modeling, along with explainable AI, are involved in improving the early detection of cancer, predicting how patients will react to treatment, and planning individualized therapies. The results show that AI systems enhance diagnostic accuracy, improve risk identification, optimize treatments, and reduce side effects and wastage. However, there are still problems. Data differences, algorithm bias, the challenge of interpreting AI outputs, and rules for using AI in medicine are all issues that are still being debated. This research provides a single framework for AI-based precision oncology that can be scaled and provides practical advice for clinicians, policy makers, and future research.

| KEYWORDS

Artificial intelligence, Big-data analytics, Personalized cancer treatment, Precision oncology, Multi-omics integration, Medical imaging, Predictive modeling

| ARTICLE INFORMATION

ACCEPTED: 01 November 2025 **PUBLISHED:** 30 November 2025 **DOI:** 10.32996/jcsts.2025.7.11.40

1. Introduction

Cancer is also one of the major causes of morbidity and mortality worldwide, burdening healthcare systems and economies. Despite the developments in screening, diagnostics, and therapeutics, cancer outcomes still remain highly variable due to the complex biological and clinical nature of the disease. Tumor heterogeneity, genetic variation, lifestyle habits, and environmental exposures all play a role in affecting the response to treatment in different patients, which results in limiting the effectiveness of the standardized protocols in oncology. Consequently, there is an emerging recognition that traditional "one size fits all" methods of treatment are inadequate for treating the multifaceted nature of cancer.

The advent of personalized medicine has revolutionized the field of oncology by taking center stage in patient-specific diagnosis and treatment. Personalized cancer treatment aims to make decisions about cancer treatment depending on a person's genetic composition, molecular biomarkers, clinical history, and lifestyle traits. The aim of this approach is to maximize therapeutic efficacy and minimize toxicity and unnecessary interventions. However, the achievement of personalized oncology relies heavily on the capacity to handle and interpret a large volume of heterogeneous healthcare data, which is beyond the sequencing capacity of conventional analytical approaches (Ahmed et al., 2025).

The beginning of massive data analytics has positioned itself as a key facilitator for individualized oncology care. The rapid growth in the use of electronic health records (EHRs), next-generation sequencing modalities, high-resolution medical imaging, and wearable health technologies has led to the generation of unprecedented health data, both structured and unstructured. These datasets provide invaluable insights into pathophysiological mechanisms, therapeutic results, and patterns of behavior of the patients; however, the complexity of these data and their sheer size present serious analytical questions. Artificial intelligence and machine spirituality have been shown to be especially efficacious in confronting these obstacles by understanding difficult patterns, modeling difficult nonlinear dynamics, and being able to derive prognostic forecasts from voluminous, multidimensional datasets (Manik, M. M. T. G., et al., 2025).

Within the oncology arena, AI-driven big data analytics are being applied across the care continuum in early detection, risk stratification, therapeutic choice, and prognostication. Machine learning with trained models based on large clinical and molecular data sets has shown strong performance in predicting disease development, therapeutic success, and general patient survival. Deep-learning methods in particular have brought strong success results in the study of medical imagery, enabling accurate tumor identification and tumor segmentation in a variety of tumors (Khair et al., 2025). These competencies shed light on the potential of artificial intelligence in transforming healthcare into more effective clinical decision-making and improvement of patient outcomes.

A great breakthrough in personalized cancer care is the use of multi-omics: genomics, transcriptomics, proteomics, and metabolomics for clinical analysis. Cancer is a disease of molecules, mainly, resulting from genetic mutations and unstable biological pathways. By integrating these types of data, we have a complete picture of how a tumor behaves. This view allows us to identify valuable biomarkers as well as to design targeted treatments. AI and machine learning tools are good at working with large, varied data sets arising from multi-omics. They find patterns that are hidden and direct precision therapy (Ahmed et al., 2025; Manik, M. M. T. G., et al., 2025).

At the same time, medical imaging has improved with AI. Deep neural networks and convolutional networks analyze scans in a lot more detail than a human can, reducing the problems of diagnosing differences and catching cancer earlier. This is particularly important with pancreatic cancer, where the anatomy is very complicated; imaging clues are subtle, and it often takes some time to get to a positive finding (Khair et al., 2025). Combining imaging-based information with molecular and clinical information gives AI systems a broad perspective of cancer diagnosis and follow-up.

Despite all of these advances, however, there are still obstacles to using AI to personalize cancer treatment. Data from various sources is inconsistent, systems don't always work together, algorithms can be biased, and it can be difficult to understand how a model is making decisions. Ethical issues such as patient privacy, informed consent, and fair access make an already complex issue even more complicated. In addition, regulatory rules often lag behind the tech: it is unclear how to validate and deploy AI tools in practice (Samiun et al., 2025).

2. Literature Review and Theoretical Framework

2.1 Evolution of Personalized Cancer Treatment

Personalized cancer treatment has arrived due to the fact that we now understand that cancer is not a single disease, but a group of highly heterogeneous diseases driven by genetic, molecular, and environmental factors. Traditional models of oncology are based on standardized regimens according to tumor location and stage, and too often fail to consider inter-patient variability and intra-tumoral heterogeneity. As a result, the outcome of treatment varies greatly; many patients have suboptimal results or severe adverse outcomes from therapies.



Figure 1. AI-Driven Big Data Framework for Personalized Cancer Treatment

Advances in molecular biology and high-throughput plastic technologies (particularly next-generation sequencing) have helped catalyze the dawn of personalized oncology. These tools provide ample opportunity to encapsulate the genomics and molecular pathways of tumor tissues in fine detail, which would enable doctors to choose actionable mutations and deliver appropriate treatment accordingly. However, the large volume and complexity generated by these technologies in molecular data necessitate advanced means of analysis that are capable of producing clinically meaningful insights (Ahmed et al., 2025).

Big data analytics offers a computational platform for personalized treatment of cancer by aggregating, integrating, and analyzing various healthcare data. When combined with the power of artificial intelligence, this analytics framework supports a shift from descriptive, reactive oncology to predictive and prescriptive care models. These models focus on the early intervention approach and individual treatment plan (Manik, M. M. T. G., et al., 2025).

2.2 Big Data Analytics in Oncology

Big data in oncology covers a broad range of available data that includes electronic health records, genomic and transcriptomic data, medical imaging, clinical trial databases, and real-world evidence data obtained from wearable and remote monitoring devices. These types of datasets are characterized by high dimensionality, heterogeneity, and speed of their generation, making the reproduction analysis for such types of mentions using conventional statistical techniques very difficult.

AI-driven big data Analytics overcomes these difficulties by drawing on machine learning algorithms with the ability to learn complex nonlinear relationships in massive data sets. Empirical studies have shown that big data analytics helps to improve care in cancer management by improving the diagnosis in the early stage, risk stratification, and optimization of treatment selection. By analyzing long-term patient data, AI models can identify patterns related to disease progression and response to treatments, thus allowing proactive and adaptive decision-making for clinical practice (Ahmed et al., 2025). In addition, big data analytics provides population-level knowledge while maintaining patient-level granularity. This dual capability is especially useful in oncology, where the integration of understanding both individual variability and broader trends associated with disease is crucial for the effective implementation of precision medicine programs.

2.3 Artificial Intelligence and Machine Learning for Clinical Decision Support

Artificial intelligence and machine learning form integral parts of the implementation of large-scale data analytics in personalized oncology. Supervised learning models, such as random forests, support vector machines, and gradient boosting algorithms, have been widely used to predict oncologic outcomes (e.g., survival probabilities, recurrence risk, and response to therapy). These models rely on labeled data sets of both clinical and molecular information to generate patient-specific predictions that have significant precision.

Deep-learning ways widen these capabilities by having the opportunity of immediate feature extraction from raw data inputs, e.g., genomic sequences and radiographic images. Deep neural networks are particularly powerful at modelling high-dimensional data and at capturing subtler patterns in the data that may be lost during traditional human analysis. Explainable AI methods, which include feature attribution and importance scoring, include extra model interpretability, making them more suitable for clinical application (Manik, M. M. T. G., et al., 2025).

Artificial Croix, Clinical Decision Support, and BED generation generate clinical decision support systems that are clinical-approaching clinical decision-making and data-analysis process, and integrating predictive models into learning clinical flow, actionable clinical, real-world setting, and generate interdependent learning input to clinicians using their people. Such systems have actually been shown to increase consistent diagnoses, lessen cognitive burden, and offer evidence-based treatment systems within the context of complicated care settings (Samiun et al., 2025).

2.4 Multi-Omics Integration in Precision Oncology

Multi-omics integration is a great breakthrough in personalized cancer therapy. It allows us to dissect the biology of our tumor in multiple molecular layers: the genomics layer, which tells us what genetic mutations have occurred, the transcriptomics layer, which informs us of what genes are active, the proteomics layer, which monitors the activity of proteins, and the metabolomics layer, which monitors changes in phytonutrients linked to cancer development.



Figure 2. Multi-Omics Integration Architecture in Precision Oncology

Each layer of omics provides important information; however, combining them together provides a fuller, more accurate picture of tumor behavior. AI and machine learning are well-suited for this purpose. They can manage large and complex datasets and identify interactions between layers that impact disease outcome. Studies have proved that multi-omics models are more predictive of treatment response and more informative of therapeutic targets than are single-omics models (Ahmed et al., 2025).

Beyond planning medications, AI-driven changes in multi-omics analysis also contribute to the discovery as well as the repurposing of drugs. Machine learning models sort through large databases of genomics to identify gene-drug interactions, make predictions about how effective a drug is, and identify potential side effects. This accelerates the process of individual therapies and reduces the percentage of clinical trial failures (Manik et al., 2025).

2.5 AI-Driven Medical Imaging in Cancer Diagnosis

Medical imaging is a critical factor in cancer detection, diagnosis, staging, and monitoring of cancer treatment. Nonetheless, conventional image interpretation is subject to inter-objective differences after all and may be restricted by subtle visual cues, especially in anatomically complicated malignancies. AI-driven medical imaging helps to overcome these limitations by using Deep Learning algorithms to automatically detect, segment, and classify tumors with excellent accuracy.



Figure 3. AI-Enabled Medical Imaging Pipeline for Cancer Diagnosis

Recent studies have shown that imaging systems operating on the deep neural network model perform close to human or better than humans in cancer detection tasks. For instance, we have seen models with outstanding accuracy in detecting pancreatic tumors in CT scans, a form of cancer that is often diagnosed late and has a low survival rate (Khair et al., 2025). These systems capitalize on sophisticated image processing algorithms, image segmentation, and classification algorithms in order to improve the diagnostic sensitivity and specificity.

The current advances in medical imaging by AI technology have further cemented the role of deep learning in precision oncology. Lightweight and hybrid architectures have had great performance while being able to keep computation efficiency adequate to be used in a clinical environment. For example, an SE-MobileViT-based model for oral cancer detection was introduced, which is highly accurate on clinically validated data sets and is less complex than the model (Kabir et al. 2025). Likewise, a hybrid deep learning-based representation that includes convolutional and transformer-based representations, for both lung cancer and colon cancer classification problems, depicted the adaptability of an artificial intelligence model across different oncology imaging areas (Sobur & Rana, 2024; Ahmad et al., 2025). These studies highlight the feasibility of scalable real-time artificial intelligence imaging solutions in personalized cancer treatment.

Beyond diagnosis, image creation that is powered by AI assists in longitudinal monitoring of tumor progression and treatment response. Automated image analysis allows objective and reproducible measurement of the tumor size and morphology and thus supports adaptive treatment planning and outcome evaluation.

2.6 Predictive Analytics and Outcome Modeling

Predictive analytics works as a building block of AI-enabled personalized cancer treatment. By combining clinical, molecular, and imaging information together, predictive models create separate risk assessments and outcome predictions. These models support early intervention strategies, treatment intensity, and provide improved resource allocation.

Empirical evidence from the predictive modelling of disease with artificial intelligence in the healthcare field shows that such systems achieve high levels of accuracy and scalability across a range of disease domains. Within the field of oncology, predictive models can provide clinicians with the ability to anticipate resistance to treatment, recurrence of the disease, and survival outcomes, aiding in the delivery of personalized and proactive care (Manik, M. M. T. G., et al., 2025).



Figure 4. Predictive Analytics and Patient Risk Stratification Model

2.7 Ethical and Regulatory Considerations in AI-Enabled Oncology

Despite the promise, AI-driven personalized oncology creates major ethical challenges as well as regulatory hurdles. Data privacy, algorithmic bias, and lack of transparency need to be tackled in order to implement AI in fair and responsible ways. When models are trained on unrepresentative data then it can aggravate health disparities, and so inclusive data practices and bias mitigation are critical. Regulatory frameworks need to evolve to support AI-based clinical tools through a set of regular rules for validation, approval, and monitoring of these tools. Education for clinicians and interdisciplinary teamwork are very important in establishing trust and smoothly incorporating AI in the daily clinical practice of oncology (Samiun et al., 2025).



Figure 5. Ethical, Regulatory, and Governance Framework

2.8 Theoretical Framework for AI-Driven Personalized Cancer Care

Based on the reviewed literature, in this study, the theory is taken from a data-driven, AI-powered ecosystem in which personalized cancer treatment is achieved. The framework integrates big-hardware data analytics, multi-omics profiling and data, AI-guided imaging, and predictive modeling in the context of an ethically managed clinical system. This integrated model emphasizes the concepts of continuous learning, flexibility, and patient-centric decision-making, which makes AI the key driver of next-generation precision oncology.

3. Methodology

3.1 Study Design and Research Paradigm

This study is based on a combined and AI-driven approach to personalizing cancer treatment with the combination of multimodal health data. Rather than an experiment on a single site, it leverages corroborated approaches from the latest peer-reviewed publications on big data analytics, precision oncology, and AI. The outcome is a scalable and reproducible framework of precision oncology with evidence (Ahmed et al., 2025). The study is based on a data-centric precision medicine model, with AI being the heart of the engine where clinically relevant insights are extracted from different biomedical data sources. The pipeline combines clinical records, multi-omics profiles, and imaging into a single AI-enabled probabilistic workflow based on robustness, interpretability, and ethical considerations (Manik, M. M. T. G., et al., 2025).

3.2 Data Sources and Multimodal Data Acquisition

Tailored cancer treatment requires a thorough representation of patient-specific biological and clinical variability. Accordingly, this study incorporates multimodal data sources commonly engaged in modern AI-driven oncology research.

Clinical data comes from both structured and unstructured electronic health records and includes patient demographics, diagnostic data, lab data, treatment history, and outcome measures. Electronic health record (EHR) data offer a longitudinal perspective on disease development and the efficacy of therapy, and aid in temporal modelling and prediction of outcomes.

Advanced techniques of natural language processing (NLP) are employed to extract salient clinical findings from unstructured text sources, such as clinician annotations and pathology reports, so as to increase phenotypic granularity and allow for comprehensive patient profiling. Empirical evidence from the field of antecedent study has shown that artificial intelligence (AI) models that combine EHR data have superior predictive accuracy and clinical-proven relevance in diverse areas of healthcare (Manik, M. M. T. G., et al., 2025).

To outline the molecular complexity inherent to carcinogenesis, in this investigation, an integrative multi-omics approach of genomics, transcriptomics, proteomics, and metabolomics is used. Genomic datasets include somatic mutations, copy number variations, and transcript abundance profiles, which we elicit the use of next-generation sequencing platforms.

The synthesis of information on multi-omics allows a complete characterization of the biology of tumors and the identification of molecular signatures for action. Machine learning based fusion algorithms are being used in order to harmonize disparate toolkits of omics strata to enable neurodivergent therapies in predictive models representing cross-modality interactions modulating therapeutic response and disease trajectory. In empirical findings, it has been shown that multi-omics driven models are superior to single-omics paradigms in precision oncology (Ahmed et al., 2025).

Medical imaging information is introduced, especially computed tomography (CT) scan, which helps in tumor detection, segmentation, and classification. Imaging data have been used to provide critical spatial and morphological data to complement molecular and clinical data sets.

This study is based on deep learning-based imaging pipelines that are validated in recent research in oncology. These pipelines include integrated image preprocessing, segmentation, and classification using deep neural networks, optimized for cancer detection tasks. AI-driven imaging models have shown their extraordinary performance with anatomically complex tumors such as pancreatic cancer, which often are very hard to detect in early stages at a clinical level (Khair et al., 2025).

3.3 Data Preprocessing and Feature Engineering

Healthcare data is diverse and large, and to ensure the analyses are reliable and the models are accurate, we need to preprocess the data with caution.

Clinical and molecular data sets are subjected to a series of operations (filling missing data values, scaling, identifying outliers, etc.) to ensure that they are physiologically representative of average human population. Statistical and machine-learning methods help to fill the gaps in the incomplete records while preserving the original structure of the data. Scaling and normalization make number values stable and also allow models to converge faster.

High-dimensional biomedical data are prone to overfitting, which can cause slower computations. Therefore, to retain the most useful predictors, we use feature-selection approaches such as recursively eliminating and explainability-driven approaches. Explainable AI tools, such as feature-attribution analysis, can help explain why a model is making a decision and establish clinical trust (Manik, M. M. T. G., et al., 2025).

Dimensionality - reduction methods consist of principal component analysis as well as representations based on autoencoders to help reduce the dimensions of multi-omics data while also allowing for biologically relevant variation to be maintained. For imaging, convolutional neural networks automatically learn hierarchical features and reduce the need for manual feature engineering (Khair et al., 2025).

3.4 Artificial Intelligence and Machine Learning Models

Our framework is an amalgamation of diverse AI and machine learning models that address various aspects of individualized treatment of cancer. We use supervised methods within processes like random forests, boosting, and deep learning applications, where we at least predict how the patient will respond to treatment, how the disease will progress, and how long the patient may live. By learning from the examples of cases with known clinical and molecular data, these models construct personal risk profiles that can be used to determine precision treatment programs.

Ensemble methods are used to combine the predictions of various models to suppress the bias and ensure better performance against various patients (Manik, M. M. T. G., et al., 2025). For identifying tumor images, we use convolutional neural networks and deep learning architectures, as well as hybrid architectures. These models use a combination of refined segmentation algorithms and deep layers of feature extraction, which distinguish features between tumor tissue and the surrounding.

We also use nature-inspired optimization and deep-learning classifiers to increase the segmentation and classification accuracy. These techniques have demonstrated almost 100% accuracy in detecting pancreatic tumors and, therefore, can be promising candidates for the early detection and diagnosis of cancer (Khair et al., 2025). Machine learning is used on genomic information to find gene-drug interactions and predict treatment effectiveness. Deep learning and reinforcement learning are used to analyze big data in genomics, thereby helping in drug discovery, drug repurposing, and personalized therapy selections. These models match the patients to treatments based on their molecular profiles, resulting in a reduction in side effects and improvements in patient outcomes. AI-primed genomics is important in bringing precision oncology and personalized cancer treatment prior to us (Manik, M. M. T. G., et al., 2025).

The framework also takes advantage of the latest research in hybrid and attention-based architectures, which was inspired by researchers combining CNNs and transformers, capsule networks, and ensemble learning. And see that combinations such as CNN-Transformer and XGBoost-Capsule networks actually improve feature representation and stability of predictions, with decent results about the data imaging and clinical data (Kabir et al., 2021; Hossain et al., 2023). These insights influence our model design and emphasize accuracy, model interpretability, and clinical feasibility.

3.5 Model Evaluation and Validation

Model performance is assessed with the use of standard criteria appropriate to each kind of analysis. For classification models, accuracy, sensitivity, specificity, recall, and F1 score are of interest. Predictive models are evaluated using the area under the receiver operating characteristic curve (AUC ROC) and using calibration measures. We use cross-validation and external validation to make sure the models have good generalization power or to reduce the effects of over-fitting. Imaging models are compared with known and accepted diagnostic systems so that they are clinically relevant and robust (Ahmed et al., 2025).

3.6 Explicability, Ethics and Governance

Explainable AI techniques become integrated throughout the analytical pipeline at points of increased transparency and to build clinician trust. Feature- and structure attribution, as well as other interpretation methods, enable emphasizing the contributing factors that are driving the predictions, aiding clinicians to make informed decisions. Ethical factors, including value for data privacy, that aim to decrease bias and abide by regulations, are an important part of our approach. We highlight secure handling of data, protocols of anonymization, and ethical governance frameworks so that AI can be dependably implemented in healthcare settings (Samiun et al., 2025).

4. Results and Integrated Findings

4.1 Overview of Analytical Results

Using big data analytics powered by Artificial Intelligence (AI) on multimodal data sets provided strong and clinically relevant results for personalized cancer care. In fields like diagnostic imaging, predictive analytics, and multi-omics drug analysis, AI systems were often found to be better than traditional analytic and rule-based processes. These findings indicate that integrating clinical information is used in precision medicine. The oncology workflow with molecular profiles and imaging intelligence can be extremely effective at enhancing the precision of the oncology workflow, thus increasing diagnostic accuracy, risk assessments, and treatment optimization (Ahmed et al., 2025). The findings are organized into four principal result domains:

1. **Diagnostic performance of AI-driven medical imaging**
2. **Predictive modeling and patient risk stratification**
3. **Multi-omics integration and molecular insight generation**
4. **Clinical decision supports personalized treatment optimization**

4.2 Diagnostic Performance of AI-Driven Medical Imaging

Deep learning-based medical imaging models have proven to have an exceptional ability to diagnose medical imagery, in particular, identifying and classifying complicated tumors. Convolutional neural network architectures and optimized deep neural network architectures were successfully applied to near-perfect performance in the identification of malignant tissues based on computed tomography images. These results are particularly relevant to pancreatic cancer detection, as Artificial Intelligence-based imaging systems have been shown to substantially reduce the rate of false negative identifications and optimize early-stage identification (Khair et al., 2025).

Compared to the traditional radiological evaluation and more conventional computer-aided diagnostic tools, AI-powered imaging models provided better sensitivity, specificity, and the ability to resist noise and anatomical non-uniformity. Advanced segmentation very accurately described the tumor boundaries, which could help with more accurate staging and treatment planning. These outcomes underscore the value of imaging that is enabled with deep learning as an important part of personalized cancer diagnosis.

Longitudinal analysis using an imaging modality reveals that AI-based systems give reliable tools to track tumor progression and response to therapy. Automated comparison of serial imaging scans provides the potential to measure tumor regression or growth more objectively, which will enable clinicians to more consistently and less subjectively evaluate the success of treatment.

4.3 Predictive Modeling and Patient Risk Stratification

Predictive analytics models have been developed based on large-scale clinical and molecular data with high accuracy and generalizability in predicting disease progression, response to treatment, and patient survival. The ensemble learning approaches and deep neural networks were shown to consistently perform well, as reflected in good values for area under the curve and balanced P-R profiles.

By combining demographic variables, EHR-derived clinical features, and medical molecular landmark biomarkers in models developed, individualized risk scores that supported early intervention and individual treatment planning were obtained. They were effective in identifying high-risk subgroups of patients, facilitating proactive clinical management of patients, and optimal distribution of healthcare resources. The findings are consistent with previous studies demonstrating the effectiveness of AI-based predictive modeling in improving the prediction of outcomes in complex areas of the disease (Manik, M. M. T. G., et al., 2025).

Explainable AI analysis showed the relative importance of predictive features and identified genomic changes, tumor morphology, and previous treatment history as some of the most influential determinants of patient-specific outcomes. This interpretability reinforced the clinical applicability of predictive models and the way they are incorporated into decision-support systems.

4.4 Multi-Omics Integration and Molecular Insights

The usage of multi-omics data, in comparison to one type of data, gives far better results for the analysis. By bringing together, using AI, genomic, transcriptomic, proteomic, and metabolomic information, researchers could describe details of tumor biology and make predictions of how patients would respond to therapy. For example, studies that incorporated all four types of data found that their models are better able to detect actionable biomarkers and resistance mechanisms, which explains why treatments sometimes fail (Ahmed et al., 2025).

AI-powered genomic models helped select the diagnosis therapy with the best treatment for each patient. They were able to determine which genes worked with which drugs and predicted the efficacy of drugs with good accuracy. This resulted in improved treatment matches with fewer side effects with improved health outcomes. The results emphasize the importance of multi-omics integration as a major element of precision oncology and treatment based on genomics (Manik et al., 2025).

4.5 Clinical Decision Support and Personalized Treatment Optimization

Predictive modeling, imaging intelligence, and multi-omics analytics in joint analysis by advanced clinical decision support. AI systems took complex data and rendered it into clear and patient-specific information, including risk-specific recommendations, diagnostic confidence scores, and prognostic information about how a patient might respond to the treatment indicated.

These outputs helped clinicians in making evidence-based decisions and moving away from trial-and-error treatments. Because the recommendations were transparent and easy to understand, AI systems enabled shared decision-making and increased consistency of care delivery. The promise represented by the use of AI in oncology workflows to make treatment faster, reduce uncertainty, and optimize patient outcomes appears to be huge (Ahmed et al., 2025; Samiun et al., 2025).

4.6 Comparative Performance Against Conventional Approaches

When compared to traditional statistical models and guideline-based clinical assessments, axiomatic big data analytics AI performed better each time. Conventional methods that are often based on a limited number of variables, which are coupled with static thresholds, were less efficient at reflecting tumor heterogeneity and patient-specific variation. AI-enabled systems were more adaptable and learned, learning to change their accuracy of prediction with incoming data. This dynamic learning ability makes AI-powered personalized oncology frameworks scalable and future-proof solutions with the ability to continue evolving with the advances in biomedical discoveries and clinical practices (Manik, M. M. T. G., et al., 2025).

The good diagnostic performance that was observed in the AI-wound imaging is complementary to findings in other domain-specific studies. Deep learning models, when applied to histopathological and radiological images, have shown high accuracy in prostate, lung, and colon cancer detection and grading. Significant improvements in grading outcomes of prostate and colon cancer, respectively, using deep learning-based computational pathology and CNN architectures, and provided consistent performances across various CNN architectures (Maniruzzaman et al. 2025 and Ahmad et al. 2025). To this end, these results collectively provide a validation of the robustness and generalizability of frameworks based on AI-enabled imaging across cancer types.

5. Discussion

5.1 Interpretation of Key Findings

This study confirms that AI-driven big data analytics represents a fundamental change in the way that cancer is now treated on a personal level. It increases diagnostic accuracy and creates personalized, tailored treatment that is not possible with traditional oncology. In integrating clinical data, multi-omics profiles, and AI-enabled medical imaging across one analysis framework, the study demonstrates how AI addresses the challenge of tumor heterogeneity, treatment resistance, and variability in treatment outcomes.

One important result of this is the excellent performance of deep learning-based imaging models for early tumor detection. They were able to obtain near-perfect success in locating complex cancers, like pancreatic cancer tumors, demonstrating the power of AI image analysis technology in real clinical settings for reducing the time needed to make a diagnosis and to enhance survival (Khair et al., 2025). These results reinforce the consensus that, from measuring resonator tags, molecular cytology imaging should serve as a front-line of diagnostic tests in precision oncology.

Similarly, predictive modeling is one of the ways to showcase AI's power in creating individual risk assessment and predicting responses to treatment. By studying large amounts of clinical and molecular data, AI models make it possible to act proactively and make a data-driven decision about which treatment to give to each patient based on their disease course. These different explainable AI techniques can keep these predictions transparent and clinically interpretable - key for adoption in practice (Manik et al., 2025).

5.2 Clinical Implications for Personalized Cancer Care

The clinical consequences of the use of AI-enabled personalized treatment of cancer are profound. Machine learning now leads to accurate diagnoses and an easier rise and rise of diseases. This leads to an improvement in patient outcomes as well as healthcare costs. The integration of multi-omics analytics helps in the appropriate selection of precision treatments for clinicians. Therapies are targeted in the context of an individual patient's particular molecular and genetic make-up, and are more likely to be effective as a result.

AI-based clinical decision support systems increase efficiency in workflows and keep the consistency the same across settings. They turn complicated, multi-dimensional data into easily understandable, patient-specific information. This helps to decrease the cognitive burden on clinicians and encourages evidence-based practice. Importantly, AI is an augmentation tool, rather than a replacement tool. It helps to strengthen human decision-making instead of undermining it (Samiun et al., 2025).

Beyond oncology, predictive models based on AI are being used in many different areas of disease. This demonstrates the generalized use of personalized analytics frameworks. Studies on the prediction of comorbidity and chronic disease evolution study data show that hybrid deep learning models comprehend complicated trajectories of risks among interrelated conditions (Hossain et al., 2023; Zakir Hossain et al., 2025). Such is the proof on the ground for the scalability of AI-enabled precision medicine, and adds to its relevance for holistic and patient-centric medicine.

5.3 Implications for Genomics-Based Drug Discovery and Therapeutic Optimization

In addition to its immediate clinical use, the results of the present study have significant implications for genomics-based drug discovery and precision therapeutics. Artificial intelligence Methods applied to large genomic datasets can be used to efficiently identify novel drug targets and can also support the drug repurposing strategy by exposing previously unknown gene-drug interactions. These capabilities will decrease the development time, cost, and chances of clinical success (Ahmed et al., 2025).

Individualized choice of therapies using AI-generated genomic data allows more effective and safe treatments to be given by predicting the likelihood of the treatment working and its side effects before clinical use. Such a shift in developing drugs from the population level to creating therapeutic solutions that target the patient is a major development in precision oncology (Manik, M. M. T. G., et al., 2025).

5.4 Ethical, Regulatory, and Societal Considerations

Though the practice of personalized oncology, enabled by artificial intelligence (AI)-powered tools, entails a transformative potential, it raises great ethical and regulatory concerns. Patient data privacy and security are of utmost importance, particularly when the to-be-dealt genome and health information are sensitive. The establishment of robust data governance processes, secure data storage, and transparent consent procedures is crucial for maintaining public trust and ensuring regulatory compliance.

This addresses the desensitization of our position: Algorithmic bias remains a key concern, as AI models developed using non-representative datasets risk perpetuating health inequities. Mitigating this problem requires inclusive data collection techniques and continued bias auditing, as well as the transparent disclosure of model limitations. Furthermore, there is a need for regulatory agencies to reduce the impact following the fast and rapid development of AI by creating explicit guidelines on validation, approval, and post-deployment monitoring of AI-based clinical tools (Samiun et al., 2025).

From a societal viewpoint, interdisciplinary cooperation between clinicians, data scientists, ethicists, and policymakers is crucial to ensure the responsible and fair use of AI technology in oncology.

5.5 Limitations of the Study

There are several limitations that should be acknowledged. First, this research is based on an integrative synthesis of extant peer-reviewed literature research, as opposed to primary experimental data, and therefore can be potentially limiting with regard to the direct comparability of performance measures across models. Second, heterogeneity in datasets, population characteristics, and evaluation methodologies of the reviewed literature may be impinging upon the generalizability of the findings. Additionally, of the AI models analyzed, a significant number are still in the pilot/pilot proof of concept stage, and to date, are limited to large-scale clinical deployment. There is an imperative need for real-world validation through prospective multi-center trials to genuinely assess the impact of these technologies on patient outcomes and healthcare systems. The ethical and regulatory issues, although discussed in concept, require further empirical work to provide evidence that may be used in future policy development.

5.6 Future Research Directions

This means future investigations should focus on the large-threatening clinical validation of chromatographic (AI) - driven personalized oncology systems across diverse populations and healthcare treatments. The establishment of standardized benchmarks and interoperable data infrastructures would improve reproducibility and the ability to compare.

Emerging methodologies like federated learning, privacy-preserving analytics, and hybrid neuro-symbolic AI provide promising possibilities to overcome the issues of data security and data interpretability. Additionally, combining real-time data from wearable devices and patient-reported outcomes could further enrich predictive modeling and enable continuous and adaptive cancer care (Manik, M. M. T. G., et al., 2025). Interdisciplinary studies of ethics, legal, and social implications of AI in oncology are likely to remain crucial to determine responsibility for innovation and equitable access to precision cancer care.

6. Conclusion

The current study shows that AI-based big data analytics is part of a transformative force in personalized cancer care, which has achieved appreciable improvements in the accuracy of cancer diagnosis, prognostic prediction, and therapeutic optimization. By integrating multi-omics data, high-tech medical imaging techniques, and predictive analytics using a centralized analytical framework, the successful use of AI-driven systems helps solve the inherent complexity and heterogeneity of malignancies. The reconsideration of consequences repeats that AI-assisted accuracy in cancer care supports early discovery, tailored treatment strategies, and better clinical decision-making procedures, and in the process reinforces the need for moral control and regulatory authorities. As expertise capabilities continue to evolve, continued interdisciplinary collaboration and clinical authorization will be vital to harness the full potential of AI in transforming cancer care. In conclusion, AI-driven big data analytics is not only an upgrade to current oncological methods but a philosophical change towards data-centric, patient-specific, and outcome-aware cancer treatment, which will therefore place precision oncology at the forefront of future healthcare innovation.

Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.

References

[1] Ahmed, M. K., Rozario, E., Mohonta, S. C., Ferdousmou, J., Saimon, A. S. M., Moniruzzaman, M., Manik, M. M. T. G., & Hasan, R. (2025). Leveraging big data analytics for personalized cancer treatment: An overview of current approaches and future directions. *Journal of Engineering*, 2025, Article 9928467. https://doi.org/10.1155/je/9928467

[2] Ahmad, M. Y., Sarker, B., Mahmud, S., & Kabir, M. F. (2025). Deep learning driven colon cancer diagnosis: Performance assessment of five convolutional neural network architectures on histopathological image classification. *American Journal of Pediatric Medicine and Health Sciences, 3*(11), 139–154. https://grnjournal.us/index.php/AJPMHS/article/view/8719

[3] Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & André, F. (2015). Precision medicine for metastatic breast cancer—Limitations and solutions. *Nature Reviews Clinical Oncology, 12*(12), 693–704. https://doi.org/10.1038/nrclinonc.2015.123

[4] Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. *JAMA, 319*(13), 1317–1318. https://doi.org/10.1001/jama.2017.18391

[5] Bibault, J.-E., Giraud, P., & Burgun, A. (2016). Big data and machine learning in radiation oncology: State of the art and future prospects. *Cancer Letters, 382*(1), 110–117. https://doi.org/10.1016/j.canlet.2016.05.033

[6] Chen, R., & Snyder, M. (2013). Promise of personalized omics to precision medicine. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 5*(1), 73–82. https://doi.org/10.1002/wsbm.1198

[7] Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., & Greene, C. S. (2018). Opportunities and obstacles for deep learning in biology and medicine. *Journal of the Royal Society Interface, 15*(141), 20170387. https://doi.org/10.1098/rsif.2017.0387

[8] Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. *New England Journal of Medicine, 372*(9), 793–795. https://doi.org/10.1056/NEJMp1500523

[9] Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature, 542*(7639), 115–118. https://doi.org/10.1038/nature21056

[10] He, K., Zhang, X., Ren, S., & Sun, J. (2016). Deep residual learning for image recognition. In *Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition* (pp. 770–778). https://doi.org/10.1109/CVPR.2016.90

[11] Hossain, M. Z., Khan, M. M., Nahar, K., & Kabir, M. F. (2023). Formulation of a multi-disease comorbidity prediction framework: A data-driven case analysis of diabetes, hypertension, and cardiovascular risk trajectories. *Journal of Computer Science and Technology Studies, 5*(3), 161–182. https://doi.org/10.32996/jcsts.2023.5.3.12

[12] Hossain, M. Z., Zakir Hossain, M., et al. (2025). Advanced classification of diabetic foot ulcers using custom and deep learning models. In *Proceedings of the IEEE International Conference on Emerging Technologies and Applications (MPSec ICETA)* (pp. 1–6). https://doi.org/10.1109/MPSecICETA64837.2025.11118338

[13] Kabir, M. F., Ahmad, M. Y., Khandakar, S., & Rahman, M. M. (2021). Hybrid deep learning framework for enhanced heart disease prediction: Integrating XGBoost and capsule networks with CNN-transformer architectures. *Journal of Computer Science and Technology Studies, 3*(2), 116–123. https://doi.org/10.32996/jcsts.2021.3.2.9

[14] Kabir, M. F., Ahmad, M. Y., Uddin, R., Khandakar, S., & Rahman, M. M. (2025). Accurate and lightweight oral cancer detection using SE-MobileViT on clinically validated image dataset. *Discover Artificial Intelligence, 5*, 173. https://doi.org/10.1007/s44163-025-00442-2

[15] Khair, F. B., Saimon, A. S. M., Hossain, S., Manik, M. M. T. G., Ahmed, M. K., Islam, M. S., & Moniruzzaman, M. (2025). Deep neural network–based imaging system for efficient pancreatic tumor identification. *Intelligent Decision Technologies, 19*(6), 4118–4129. https://doi.org/10.1177/18724981251381581

[16] Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2015). Machine learning applications in cancer prognosis and prediction. *Computational and Structural Biotechnology Journal, 13*, 8–17. https://doi.org/10.1016/j.csbj.2014.11.005

[17] Libbrecht, M. W., & Noble, W. S. (2015). Machine learning applications in genetics and genomics. *Nature Reviews Genetics, 16*(6), 321–332. https://doi.org/10.1038/nrg3920

[18] Litjens, G., Kooi, T., Bejnordi, B. E., Setio, A. A. A., Ciompi, F., Ghafoorian, M., & Sánchez, C. I. (2017). A survey on deep learning in medical image analysis. *Medical Image Analysis, 42*, 60–88. https://doi.org/10.1016/j.media.2017.07.005

[19] Manik, M. M. T. G., Mohonta, S. C., Karim, F., Miah, M. A., Islam, M. S., Chy, M. A. R., Adnan, M., & Saimon, A. S. M. (2025). AI-driven precision medicine leveraging machine learning and big data analytics for genomics-based drug discovery. *Journal of Posthumanism, 5*(1), 1560–1580. https://doi.org/10.63332/joph.v5i1.1993

[20] Manik, M. M. T. G., Saimon, A. S. M., Ahmed, M. K., Hossain, S., Moniruzzaman, M., & Islam, M. S. (2025). Predictive modelling for early detection of type 2 diabetes using AI-driven machine learning algorithms and big data analytics. In J. C. Bansal et al. (Eds.), *Advances in Intelligent Systems and Computing* (LNNS Vol. 1629, pp. 422–433). Springer. https://doi.org/10.1007/978-3-032-05548-4_33

[21] Maniruzzaman, M., Rana, M. I. C., Kabir, M. F., Ahmad, M. Y., Rahat, I. S., & Ghosh, H. (2025). Integrating deep learning in prostate cancer grading: Innovations in computational pathology. In S. N. Mohanty, Á. Rocha, & P. K. Dutta (Eds.), *Artificial Intelligence in Oncology*. Springer. https://doi.org/10.1007/978-3-031-94302-7_27

[22] Manik, Mia Md Tofayel Gonee, Hossain, Sazzat, Ahmed, Md Kamal, Rozario, Evha, Miah, Md Alamgir, Moniruzzaman, Mohammad, Islam, Md Shafiqul, Saimon & Abu Saleh Muhammad (2022). Integrating Genomic Data and Machine Learning to Advance Precision Oncology and Targeted Cancer Therapies. Nanotechnology Perceptions, Vol. 18 No. 2 (2022), 219-243, https://doi.org/10.62441/nano-ntp.v18i2.5443

[23] Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018). Deep learning for healthcare: Review, opportunities and challenges. *Briefings in Bioinformatics, 19*(6), 1236–1246. https://doi.org/10.1093/bib/bbx044

[24] Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future—Big data, machine learning, and clinical medicine. *New England Journal of Medicine, 375*(13), 1216–1219. https://doi.org/10.1056/NEJMp1606181

[25] Rajkomar, A., Dean, J., & Kohane, I. S. (2019). Machine learning in medicine. *New England Journal of Medicine, 380*(14), 1347–1358. https://doi.org/10.1056/NEJMra1814259

[26] Razzak, M. I., Imran, M., & Xu, G. (2019). Big data analytics for preventive medicine. *Neural Computing and Applications, 32*, 4417–4451. https://doi.org/10.1007/s00521-019-04095-y

[27] Samiun, M., Rony, M. K. K., Yeasmin, S., Manik, M. M. T. G., Debnath, A., Aziz, M. B., Tasnim, A. F., & Nilima, S. I. (2025). The role of artificial intelligence in managing hospitalized patients with mental illness: A scoping review. *Discover Public Health, 22*, Article 421. https://doi.org/10.1186/s12982-025-00814-0

[28] Sharma, R., et al. (2024). A novel classification scheme for early Alzheimer's disease severity diagnosis using deep features of a hybrid cascade attention architecture. In *Proceedings of the International Conference on Augmented Reality, Intelligent Systems, and Industrial Automation (ARIIA)* (pp. 1–6). https://doi.org/10.1109/ARIIA63345.2024.11051777

[29] Shortliffe, E. H., & Sepúlveda, M. J. (2018). Clinical decision support in the era of artificial intelligence. *JAMA, 320*(21), 2199–2200. https://doi.org/10.1001/jama.2018.17163

[30] Sobur, A., & Rana, I. C. (2024). Advancing cancer classification with hybrid deep learning: Image analysis for lung and colon cancer detection. *International Journal of Creative Research Thoughts (IJCRT)*. https://ssrn.com/abstract=4853237

[31] Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine, 25*(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

[32] Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., & Williams, P. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery, 18*(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5

[33] Way, G. P., & Greene, C. S. (2018). Extracting a biologically relevant latent space from cancer transcriptomes with variational autoencoders. *Pacific Symposium on Biocomputing*, 80–91. https://doi.org/10.1142/9789813235533_0008

[34] Yu, K.-H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. *Nature Biomedical Engineering, 2*(10), 719–731. https://doi.org/10.1038/s41551-018-0305-z

[35] Zhang, Z., Sejdić, E., & Guo, Y. (2021). Radiomics and machine learning in cancer treatment response prediction. *Physics in Medicine & Biology, 66*(10), 10TR01. https://doi.org/10.1088/1361-6560/abf40b